Information  X 
Enter a valid email address

C4X Discovery (C4XD)

  Print   

Thursday 01 July, 2021

C4X Discovery

Total Voting Rights

RNS Number : 8699D
C4X Discovery Holdings PLC
01 July 2021
 

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Exercise of Warrants,

Exercise of Options,

Block Listing Application

and

Issue of Equity

 

 

1 July 2021 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces that it has received notices to exercise options and warrants over, in aggregate, 286,070 new ordinary shares of £0.01 in the Company ("Ordinary Shares"). Further details are below.

 

Exercise of Warrants

 

A warrant holder has exercised warrants to subscribe for 178,570 new Ordinary Shares (the "Warrant Shares"), at an exercise price of 28 pence per warrant and for which funds have been received by the Company.


Exercise of Options

 

An employee of the Company has exercised options to subscribe for 107,500 new Ordinary shares (the "Option Shares"), at an exercise price of 5.58 pence per option and for which funds have been received by the Company.

 

Admission and Total Voting Rights

 

Application has been made for the   178,570 Warrant Shares and 107,500 Option Shares to be admitted to trading on AIM and dealings are expected to commence on or around 8.00 a.m. on 7 July 2021. The Warrant Shares and the Options Shares will rank pari passu with the existing ordinary shares. 

 

Block Listing Application

 

In addition, an application has also been made for admission to AIM for a block listing of 106,964,288 ordinary shares of £0.01 each in the Company ("Block Listing Shares"), in respect of the balance of warrants over shares.

The Block Listing Shares will not be allotted immediately, but rather will be issued and allotted from time to time pursuant to the exercise of warrants granted and announced on 9 November 2020. Upon exercise, these Block Listing Shares will be issued as fully paid and will rank pari passu in all respects with the existing ordinary shares of the Company.

Total Voting Rights

 

Upon admission of the Warrant Shares and Option Shares to trading on AIM, the Company's issued share capital will consist of 226,712,697 ordinary shares. Accordingly, the figure of 226,712,697 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

Contacts

 

C4X Discovery Holdings


Mo Noonan, Communications

+44 (0)787 6444977



Panmure Gordon (UK) Limited (NOMAD and Broker)


Freddy Crossley, Emma Earl (Corporate Finance)

+44 (0)20 7886 2500

Rupert Dearden (Corporate Broking)




C4X Discovery Media - Consilium Strategic Communications


Mary-Jane Elliott, Chris Gardner, Matthew Neal

+44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

 

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines, which are developed by our partners for the benefit of patients.  We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, neurodegeneration, oncology and addictive disorders.  Our commercially attractive portfolio ranges from early stage novel target opportunities to late stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development.  Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.  For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRDKDBQKBKDFOK

a d v e r t i s e m e n t